Abstract

Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call